Core Insights - The core viewpoint of the news is that Hendi Pharmaceutical experienced significant declines in revenue and profit in 2024, primarily due to reduced sales of its core product, ibuprofen raw materials, and low international market prices [2][4] Financial Performance - In 2024, Hendi Pharmaceutical achieved operating revenue of 445 million yuan, a year-on-year decrease of 32.75% [2] - The net profit attributable to shareholders was 91.54 million yuan, down 48.02% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 72.95 million yuan, a decline of 57.14% year-on-year [2] - Basic earnings per share were 0.32 yuan [2] Revenue Breakdown - The decline in operating revenue was mainly due to a decrease in sales volume of ibuprofen raw materials and low international market prices [4] - The raw materials segment generated revenue of 356 million yuan, accounting for 79.88% of total revenue [4] - The formulation segment contributed 85 million yuan, representing 19.11% of total revenue [4] Product Performance - Revenue from non-steroidal anti-inflammatory drugs (ibuprofen) was 317 million yuan, down 40.69% year-on-year, making up 71.15% of total revenue [4] - The cardiovascular segment saw revenue of 63.49 million yuan, a slight increase of 1.10% year-on-year, with stable performance from products like Torasemide tablets [4] R&D and Future Plans - R&D investment in 2024 was 32.94 million yuan, a decrease of 37.59% year-on-year, with the R&D expense ratio dropping to 7.39% [4] - The company added one new Chinese invention patent and several products entered the technical review stage [4] - The high-end pharmaceutical formulation internationalization project has been postponed to 2026, focusing on the coordinated development of raw materials and formulations [4]
亨迪药业2024年净利润下滑48% 布洛芬销售惨淡